An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel.
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2014
At a glance
- Drugs Docetaxel (Primary) ; Lonafarnib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 31 Aug 2018 Biomarkers information updated
- 28 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 May 2010 Planned end date changed from 1 Feb 2012 to 1 Dec 2009 as reported by ClinicalTrials.gov.